# US 2020/0390877 A1 · Formulations of dengue virus vaccine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390877 A1
- Document ID: US20200390877A1
- Status: Published application
- Kind: A1
- Application number: 16/769,837
- Filed: 2018-12-03
- Published: 2020-12-17
- Earliest claimed: 2017-12-07
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Michael S. Ryan; Sherrie-Ann P. Martin; Morrisa Jones; Justin Stanbro; Akhilesh Bhambhani; Jeffrey Thomas Blue; Heidi Joanne Pixley; Erin J. Green-Trexler; Lynne Ann Isopi
- Web page: https://patentgrep.com/patent/US20200390877A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/12: Viral antigens
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.

## Claims

### Claim 1

A formulation comprising a live attenuated dengue vaccine comprising at least one live attenuated dengue virus (LAV) or at least one live attenuated chimeric flavivirus (LACV), a buffer at pH about 6.5 to 8.5, a sugar, a glycol or sugar alcohol, and a cellulose derivative selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), 2-hydroxyethyl cellulose (2-HEC), crosscarmellose, and methyl cellulose, or a pharmaceutically acceptable salt thereof, and optionally an alkali or alkaline salt and/or an amino acid selected from the group consisting of Ala, Asp, His, Leu, Lys, Gln, Pro, Glu, and a combination thereof.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the buffer is selected from the group consisting of succinate, histidine, phosphate, TRIS, Bis-Tris, MES, MOPS, HEPES, acetate, citrate, and a combination thereof.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the alkali or alkaline salt is magnesium chloride, calcium chloride, potassium chloride, sodium chloride or a combination thereof.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the sugar is trehalose or sucrose.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the cellulose derivative is a pharmaceutically acceptable salt of carboxymethyl cellulose.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the glycol is selected from the group consisting of propylene glycol, polypropylene glycol, ethylene glycol, polyethylene glycol, and polyethylene glycol monomethyl ethers.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein the glycol or sugar alcohol is propylene glycol or glycerol.

### Claim 8 (depends on 1)

The formulation of claim 1 that comprises a live attenuated dengue vaccine comprising at least one live attenuated dengue virus (LAV) or at least one live attenuated chimeric flavivirus at about 100-10,000,000 pfu/ml, a buffer at pH about 6.5 to 8.5, about 50-300 mg/ml sugar, about 2.5-10.0 mg/ml propylene glycol (PG) or glycerol, and about 0.3-10 mg/ml sodium carboxymethylcellulose (sodium CMC), and optionally about 10-150 mM NaCl and/or about 10-100 mM amino acid selected from the group consisting of Ala, Asp, His, Leu, Lys, Gln, Pro, Glu and a combination thereof.

### Claim 9 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 100-100,000 pfu/ml, about 5-300 mM histidine, TRIS, Bis-Tris or phosphate buffer, or a combination thereof at pH about 7.0 to 8.0, about 50-300 mg/ml sugar, about 3-10 mg/ml propylene glycol or glycerol, and about 3-10 mg/ml sodium carboxymethylcellulose, and optionally about 15-75 mM NaCl and/or about 10-75 mM amino acid selected from the group consisting of Ala, Asp, His, Leu, Lys, Gln, Pro, Glu and a combination thereof.

### Claim 10 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 5-300 mM potassium phosphate buffer at pH about 7.0-8.0, about 60-120 mg/ml sucrose or trehalose or a combination thereof, about 3-7 mg/ml propylene glycol or glycerol, and about 3-7 mg/ml sodium carboxymethylcellulose with average molecular weight of about 90,000, and about 30-90 mM NaCl, and optionally about 10-75 mM amino acid Leu, Lys or Glu, or a combination thereof.

### Claim 11 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 11 mM potassium phosphate buffer at pH about 7.0-8.0, about 90 mg/ml sucrose, about 5 mg/ml propylene glycol or glycerol, about 5 mg/ml sodium carboxymethylcellulose with average molecular weight of about 90,000, and about 75 mM NaCl.

### Claim 12 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 11 mM potassium phosphate buffer at pH about 7.0-8.0, about 90 mg/ml sucrose, about 5 mg/ml propylene glycol, about 5 mg/ml sodium carboxymethylcellulose with average molecular weight of about 90,000, about 50 mM NaCl, and about 25 mM Leu.

### Claim 13 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 11 mM potassium phosphate buffer at pH about 7.5, about 90 mg/ml sucrose, about 5 mg/ml propylene glycol, about 5 mg/ml sodium carboxymethylcellulose with average molecular weight of about 90,000, and about 30 mM NaCl.

### Claim 14 (depends on 9)

The formulation of claim 9, further comprising about 90-200 mg/ml trehalose.

### Claim 15 (depends on 1)

The formulation of claim 1 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 11 mM potassium phosphate buffer at pH about 7.5-8, about 90 mg/ml sucrose, about 110 mg/ml trehalose, about 5 mg/ml propylene glycol, about 5 mg/ml sodium carboxymethylcellulose with average molecular weight of about 90,000, about 50 mM NaCl, and about 25 mM Leu.

### Claim 16 (depends on 1)

The formulation of claim 1, wherein the formulation further comprises a surfactant selected from poloxamer 188 and poloxamer 407 at about 0.0001 to 5% w/v.

### Claim 17

A formulation that comprises a live attenuated dengue vaccine comprising at least one live attenuated dengue virus (LAV) or at least one live attenuated chimeric flavivirus at about 20-200,000,00 pfu/ml, a buffer at pH about 6.5 to 8.5, a sugar at about 150-300 mg/ml, a carrier selected from the group consisting of polyvinylpyrrolidone (PVP), carboxymethyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), 2-hydroxyethyl cellulose (2-HEC), crosscarmellose, and methyl cellulose or a pharmaceutically acceptable salt thereof, Human Serum Albumin (HSA) and gelatin; and optionally an alkali salt or alkaline salt at about 5-100 mM and/or an amino acid Gln, Pro or Glu, or a combination thereof.

### Claim 18 (depends on 17)

The formulation of claim 17, wherein the buffer is selected from the group consisting of succinate, histidine, phosphate, TRIS, Bis-Tris, MES, MOPS, HEPES, acetate, citrate, and a combination thereof.

### Claim 19 (depends on 17)

The formulation of claim 17, wherein the alkali or alkaline salt is magnesium chloride, calcium chloride, potassium chloride, sodium chloride or a combination thereof.

### Claim 20 (depends on 17)

The formulation of claim 17, wherein the sugar is trehalose or sucrose, or a combination thereof.

### Claim 21 (depends on 20)

The formulation of claim 20, wherein the sucrose to trehalose ratio is between 1:1 to 1:4.

### Claim 22 (depends on 17)

The formulation of claim 17, wherein the carrier is a sodium carboxymethyl cellulose, HPMC, HSA or gelatin.

### Claim 23 (depends on 17)

The formulation of claim 17 that comprises the live attenuated dengue vaccine at about 100-10,000,000 pfu/ml, a buffer at pH about 6.5-8.0, about 150-300 mg/ml sugar as a combination of sucrose and trehalose, about 0.3 to 40 mg/ml sodium CMC, HSA, HPMC or gelatin, and optionally about 10-100 mM alkali or alkaline salt and/or about 5-25 mM glutamic acid.

### Claim 24 (depends on 17)

The formulation of claim 17 that comprises the live attenuated dengue vaccine at about 100-100,000 pfu/ml, about 5-300 mM histidine, TRIS or phosphate buffer, or a combination thereof at pH about 7.0 to 8.0, about 50-100 mg/ml sucrose, about 90-200 mg/ml trehalose, about 0.3-10 mg/ml sodium CMC or about 10-40 mg/ml gelatin, and about 30-90 mM alkali or alkaline salt.

### Claim 25 (depends on 17)

The formulation of claim 17 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 5-20 mM potassium phosphate at pH about 7.0-8.0, about 75 mg/ml sucrose, about 175 mg/ml trehalose, about 5 mg/ml sodium CMC with average molecular weight of about 90,000, and about 30 mM NaCl.

### Claim 26 (depends on 17)

The formulation of claim 17 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 5-20 mM potassium phosphate at pH about 7.0-8.0, about 75 mg/ml sucrose, about 175 mg/ml trehalose, about 25 mg/ml gelatin, and about 30 mM NaCl.

### Claim 27 (depends on 17)

The formulation of claim 17 that comprises the live attenuated dengue vaccine at about 600-20,000 pfu/ml, about 5-20 mM potassium phosphate at pH about 7-8, about 250 mg/ml sucrose, and about 50 mg/ml PVP K12.

### Claim 28 (depends on 17)

The formulation of claim 17, further comprising a surfactant selected from poloxamer 188 and poloxamer 407 at about 0.0001 to 5% w/v.

### Claim 29 (depends on 1)

The formulation of claim 1 that further comprises an aluminum adjuvant.

### Claim 30 (depends on 1)

The formulation of claim 1 that is frozen or lyophilized.

### Claim 31 (depends on 8)

The formulation of claim 8 that is reconstituted in solution.

### Claim 32 (depends on 8)

The formulation of claim 8 that is an aqueous solution prior to lyophilization or microwave vacuum drying.

### Claim 33 (depends on 31)

The formulation of claim 31, wherein the reconstitution is performed with solution is about 0.5-1.0 ml saline solution, water or Bacteriostatic Water for Injection (BWFI) and optionally comprises a diluent comprising an aluminum adjuvant.

### Claim 34 (depends on 1)

The formulation of claim 1, wherein the live attenuated dengue vaccine is tetravalent.

### Claim 35 (depends on 1)

The formulation of claim 1, wherein the LAV or the LACV comprise a viral genome that contains a deletion of about 30 nucleotides corresponding to the TL-2 stem-loop structure of the 3′ untranslated (UTR) region (UTR).

### Claim 36 (depends on 1)

The formulation of claim 1, wherein the live attenuated dengue virus (LAV) comprises a viral genome that contains a deletion of about 30 nucleotides corresponding to the TL-2 stem-loop structure of the 3′ untranslated (UTR) region (UTR), and is immunogenic against dengue serotype 3, wherein the viral genome of the LAV further contains a deletion of nucleotides upstream from the Δ30 deletion corresponding to the TL-3 structure of the 3′UTR.

### Claim 37 (depends on 1)

The formulation of claim 1, wherein the live attenuated dengue virus (LAV) comprises rDEN1Δ30, rDEN2/4Δ30, rDEN3Δ30/31, and rDEN4Δ30.

### Claim 38 (depends on 1)

The formulation of claim 1, wherein the live attenuated dengue virus (LAV) comprises rDEN1Δ30-1545, rDEN2/4Δ30 (ME)-1495,7163, rDEN3Δ30/31-7164, and rDEN4Δ30-7132,7163,8308.
